# Liraglutide

Liraglutide is FDA-approved as Victoza and Saxenda, and as generics, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk in diabetes. It is still on FDA's shortage list. Pharmacy copies are not approved.

Status checked: 2026-10-25. Last verified: 2026-10-25. Primary source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321

This page has not been individually reviewed by a clinician.

Information, not medical advice.

| Fact | Value | Tier | Checked | Source |
|---|---|---|---|---|
| Also called | Victoza, Saxenda | primary | 2026-10-25 | [source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143) |
| Class | glp-1-agonist | primary | 2026-10-25 | [source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4) |
| Regulatory status | fda-approved | primary | 2026-10-25 | [source](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321) |
| Status source read | 2026-10-24 | primary | 2026-10-25 | [source](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341) |
| Evidence grade | strong-human | our assessment | 2026-10-25 | [source](https://peptideindex.ai/methodology#evidence-grade) |
| Label dosing | From the Victoza label and the Saxenda label. Both are shots under the skin once a day. Victoza starts at 0.6 mg a day for one week, then 1.2 mg a day, and the most is 1.8 mg a day. The Saxenda label says Saxenda starts at 0.6 mg a day and goes up each week until it reaches 3 mg a day. Children who cannot take 3 mg may stay at 2.4 mg a day. The prescriber sets the dose. | primary | 2026-10-25 | [source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4) |

## Name

Liraglutide

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

## Summary

A prescription drug that acts like the hormone GLP-1. FDA approved it as Victoza for type 2 diabetes and as Saxenda for weight loss.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

## Short answer

Liraglutide is FDA-approved as Victoza and Saxenda, and as generics, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk in diabetes. It is still on FDA's shortage list. Pharmacy copies are not approved.

Source: https://peptideindex.ai/methodology#short-answer

## Known risks

- In rats and mice, liraglutide caused thyroid tumors. The labels tell people with a rare thyroid cancer, or that cancer in the family, not to use it [^3] [^4].
- The most common problems are nausea, diarrhea, vomiting, less hunger, upset stomach and constipation [^3] [^4]. In a teen weight trial, about 1 in 10 on it stopped because of unwanted effects. Nobody on the dummy shot stopped [^17].
- The labels warn of a swollen pancreas and gallbladder disease. They also warn of kidney harm from losing fluids, and of bad allergic reactions [^3] [^4].
- Taken with insulin or some other diabetes drugs, it can push blood sugar too low. Children on Victoza had low blood sugar more often, even without insulin [^3].
- Saxenda can raise the heart rate, and its label says to check it often. It may harm an unborn baby, so the label says to stop it in pregnancy [^4].
- A 2025 review of 24 trials in adults with obesity found it may raise the chance of serious unwanted effects [^18].

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

## What nobody knows yet

- Nobody knows if it can cause thyroid cancer in people. The rodent studies do not tell us [^3] [^4].
- A 2025 review rated the size of the weight loss as very uncertain. Most of its trials were paid for by the maker [^18].
- Teens in a weight trial regained some of the loss once they stopped. The trial does not show what happens years later [^17].
- In adults with obesity, the 2025 review could not tell if it changes the risk of death [^18].
- Nobody knows how closely pharmacy copies match the approved drug. FDA does not approve them, and their raw powder may come from plants that broke its rules [^10] [^11].

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

## What it is

Liraglutide is a prescription drug. It is made to act like GLP-1, a hormone the body makes [^3]. It helps the body control blood sugar, and it makes people eat less [^3] [^4]. FDA first approved it in 2010 [^1]. One company sells it under two brand names, and FDA has approved generic versions of both [^1] [^2] [^5] [^6].

Victoza is a daily shot for type 2 diabetes [^3]. Saxenda is a daily shot for weight loss, used with diet and exercise [^4]. Both hold the same drug, so the labels say not to use them together [^3] [^4]. The body clears half of a dose in about 13 hours [^3]. That is why it is taken every day.

Some pharmacies make their own copies of it. Those copies are not FDA-approved [^10].

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

## Where it stands legally

Liraglutide is FDA-approved: FDA approved it as Victoza in January 2010 and as Saxenda in December 2014 [^1] [^2]. That covers the brand drugs and their approved generics, with a prescription, for the uses on their labels. It does not make copies from pharmacies approved [^10]. Checked 24 October 2026.

Victoza is approved for type 2 diabetes, not for weight loss. Saxenda is the one approved for weight loss [^3] [^4]. FDA approved the first generic of Victoza in December 2024 [^5]. It approved the first generic of Saxenda in August 2025 [^6].

Liraglutide has been on FDA's drug shortage list since July 2023, and it is still there [^7]. Generic versions are listed as available, and the brands have limited supply [^7]. The maker plans to stop making Saxenda in January 2027 [^7].

While a drug is on that list, outsourcing facilities may make it from raw powder [^8] [^9]. In April 2026, FDA proposed keeping liraglutide off the list of raw ingredients those facilities may use. The proposal is not final [^8] [^12]. If it becomes final, they could not make it from raw powder once the shortage ends [^12]. FDA generally treats a drug as available once its shortage ends. A pharmacy then may not make regular copies of it [^9]. Every copy must meet the compounding rules in federal law, and a website may not suggest a copy is FDA-approved [^10].

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341

## What the evidence shows

The evidence grade is strong-human: large trials in people agree that it lowers blood sugar and weight [^14] [^15] [^16]. In a heart trial of 9,340 adults with type 2 diabetes and high heart risk, fewer people on it had a heart attack, a stroke or a heart death. Over about 4 years, that was 13.0% on it and 14.9% on a dummy shot [^14]. In a 56-week trial of 3,731 adults with obesity and no diabetes, people on it lost about 8.4 kg. People on the dummy shot lost about 2.8 kg [^15]. In a trial of 134 children aged 10 to 16 with type 2 diabetes, it lowered blood sugar more than a dummy shot over 52 weeks [^16]. In a 56-week trial of 251 teens with obesity, it lowered body size more than a dummy shot [^17].

A 2025 review of 24 trials in adults with obesity found it likely helps more people lose at least 5% of their weight. It rated the size of the loss as very uncertain [^18]. A 2023 review of seven trials in children and teens found small drops in weight and blood sugar [^19].

The maker paid for these four trials, with government help on the heart trial [^14] [^15] [^16] [^17]. They tested the approved drug. They tell us nothing about copies made by pharmacies, which FDA has not approved [^10].

Source: https://pubmed.ncbi.nlm.nih.gov/27295427/

## Legitimate ways to get it

The legal way to get liraglutide is a prescription for Victoza, Saxenda or an approved generic [^1] [^2] [^5] [^6]. Each brand label says who it is for and how it is taken [^3] [^4].

Supply is still tight. Liraglutide is on FDA's shortage list, and the brands have limited supply [^7]. Saxenda is due to stop in January 2027 [^7]. The approved generic of Saxenda is for the same weight-loss use [^6].

While the shortage lasts, outsourcing facilities may make copies from raw powder [^8] [^9]. FDA does not approve these copies [^10]. FDA has proposed ending that path, and the proposal is not final [^8].

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341

## How people are getting it anyway

This section describes what happens and is not a recommendation.

Liraglutide reaches people outside the approved brands and generics in three main ways [^10] [^11]. The first is copies made by pharmacies and outsourcing facilities. Pharmacies that make copies for one patient do not have to meet factory quality rules. So a problem in the raw powder may not be caught [^11]. The second is websites that offer these copies. In February 2026, FDA warned a website whose claims suggested its liraglutide copies were approved. Its pictured label also named a business that did not make the drug [^10]. In June 2026, FDA sent 25 more such letters, one of them about liraglutide [^13]. The third is raw powder shipped from other countries. FDA checked 48 sites that make raw GLP-1 powder. It found 21% broke its rules or did not answer its requests in time [^11]. Its border staff may hold such shipments without testing them [^11].

FDA has not checked any of these copies for safety or whether they work [^10]. No FDA page we found names fake liraglutide, so this page does not describe that channel.

Source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html

## Access routes

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341

### Approved product

Detail: Approved by FDA and sold with a prescription as a daily shot for type 2 diabetes.

Brand names: Victoza

Manufacturer: Novo Nordisk

Indication: Type 2 diabetes in adults and children 10 and older, and lower heart risk in adults with type 2 diabetes and heart disease.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

### Approved product

Detail: Approved by FDA and sold with a prescription as a daily shot for weight loss.

Brand names: Saxenda

Manufacturer: Novo Nordisk

Indication: Weight loss with diet and exercise in adults and children 12 and older with obesity who weigh more than 60 kg, and in adults with overweight and a related health problem.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

### Lawful compounding

Detail: Liraglutide is still on FDA's drug shortage list. While it stays there, outsourcing facilities may make it from raw powder. FDA has proposed keeping it off their list of allowed raw ingredients, so this path would close when the shortage ends. The proposal is not final.

Source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

## Unofficial channels

Source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html

### Compounding outside the rules

What it is: Copies of liraglutide made by pharmacies and outsourcing facilities, often from raw powder made abroad.

Legal position: Outsourcing facilities may make it from raw powder only while it is on FDA's shortage list or on their list of allowed ingredients. FDA has proposed keeping it off that list. (source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list)

Documented risks:

- FDA found that 21% of 48 sites making raw GLP-1 powder broke its manufacturing rules or did not answer its records requests in time. (source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html)
- Pharmacies compounding for one patient are exempt from factory quality rules, so FDA says a problem in the raw powder may not be caught. (source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html)

Enforcement:

- 2026-04-30: FDA proposed keeping liraglutide off the list of raw ingredients outsourcing facilities may use. The proposal is not final. (source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list)

Source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

### Telehealth

What it is: Websites that offer compounded liraglutide straight to consumers.

Legal position: FDA says a site may not suggest a compounded copy is FDA-approved, or show a label naming a business that did not make it. (source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026)

Documented risks:

- FDA found a site whose pictured label named a business that did not make the drug, so buyers could not tell who made it. (source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026)
- FDA says compounded copies are not approved and have not been checked for safety or whether they work. (source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026)

Enforcement:

- 2026-02-20: FDA warning letter to a website offering compounded liraglutide and semaglutide, for claims that suggested the copies were approved. (source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026)

Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026

### Overseas or import

What it is: Raw liraglutide powder shipped into the US from makers in other countries.

Legal position: FDA lets its border staff hold shipments of raw GLP-1 powder without testing them, unless the maker is on its list of plants that meet its rules. (source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html)

Documented risks:

- FDA has seen sites register as GLP-1 powder makers, refuse its records requests, and then drop their registration within a short time. (source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html)

Enforcement:

- 2026-10-09: FDA revised Import Alert 66-80, which covers raw liraglutide and other GLP-1 powders made abroad. (source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html)

Source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html

## Recruiting trials

Snapshot date: 2026-10-25.

A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record.

- nct NCT07787936, url https://clinicaltrials.gov/study/NCT07787936, phase Not stated, title GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry, status not-yet-recruiting, sponsor Miedziowe Centrum Zdrowia SA, countries Poland, us states none listed
- nct NCT07027969, url https://clinicaltrials.gov/study/NCT07027969, phase Phase 4, title Metabolic Surgery for Atrial Fibrillation Elimination, status not-yet-recruiting, sponsor Ali Aminian, countries United States, us states Ohio
- nct NCT07881783, url https://clinicaltrials.gov/study/NCT07881783, phase Not stated, title A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy, status not-yet-recruiting, sponsor Novartis Pharmaceuticals, countries none listed, us states none listed
- nct NCT07702461, url https://clinicaltrials.gov/study/NCT07702461, phase Not stated, title Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists, status recruiting, sponsor Ohio State University, countries United States, us states Ohio
- nct NCT06726577, url https://clinicaltrials.gov/study/NCT06726577, phase Phase 1/Phase 2, title TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis, status recruiting, sponsor Talengen Institute of Life Sciences, Shenzhen, P.R. China., countries China, us states none listed
- nct NCT07301437, url https://clinicaltrials.gov/study/NCT07301437, phase Phase 4, title RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients., status not-yet-recruiting, sponsor The Fourth Affiliated Hospital of Zhejiang University School of Medicine, countries none listed, us states none listed
- nct NCT07107334, url https://clinicaltrials.gov/study/NCT07107334, phase Phase 2, title A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia, status recruiting, sponsor University of Florida, countries United States, us states Florida
- nct NCT06836284, url https://clinicaltrials.gov/study/NCT06836284, phase Not applicable, title The Evira Study: Additional Support During Obesity Treatment, status recruiting, sponsor Karolinska Institutet, countries Sweden, us states none listed
- nct NCT07225816, url https://clinicaltrials.gov/study/NCT07225816, phase Phase 1, title Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected), status recruiting, sponsor Novo Nordisk A/S, countries United States, us states California
- nct NCT06976619, url https://clinicaltrials.gov/study/NCT06976619, phase Phase 2, title The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes, status recruiting, sponsor Mayo Clinic, countries United States, us states Minnesota
- nct NCT06903923, url https://clinicaltrials.gov/study/NCT06903923, phase Phase 2, title Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy, status recruiting, sponsor University of Virginia, countries United States, us states Virginia
- nct NCT07042672, url https://clinicaltrials.gov/study/NCT07042672, phase Not stated, title Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity, status recruiting, sponsor Haukeland University Hospital, countries Norway, us states none listed
- nct NCT07094568, url https://clinicaltrials.gov/study/NCT07094568, phase Not stated, title Tirzepatide vs Liraglutide in Bone, status recruiting, sponsor National and Kapodistrian University of Athens, countries Greece, us states none listed
- nct NCT06742710, url https://clinicaltrials.gov/study/NCT06742710, phase Phase 4, title Liraglutide Treatment in Obese Infertile PCOS Women, status recruiting, sponsor Peking University Third Hospital, countries China, us states none listed
- nct NCT07029009, url https://clinicaltrials.gov/study/NCT07029009, phase Phase 2, title Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY), status recruiting, sponsor Mansa, countries United States, us states Ohio
- nct NCT06865365, url https://clinicaltrials.gov/study/NCT06865365, phase Phase 4, title Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone, status not-yet-recruiting, sponsor Medical University of Vienna, countries none listed, us states none listed
- nct NCT07244003, url https://clinicaltrials.gov/study/NCT07244003, phase Phase 4, title Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control, status recruiting, sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., countries China, us states none listed
- nct NCT06361238, url https://clinicaltrials.gov/study/NCT06361238, phase Phase 3, title Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery, status recruiting, sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, countries China, us states none listed
- nct NCT06374875, url https://clinicaltrials.gov/study/NCT06374875, phase Phase 4, title Fibrosis Lessens After Metabolic Surgery, status recruiting, sponsor The Cleveland Clinic, countries United States, Brazil, Canada, Finland, India, Ireland, Italy, Kuwait, Mexico, Spain, Sweden, Switzerland, United Kingdom, us states Arizona, Indiana, Minnesota, Ohio
- nct NCT06686134, url https://clinicaltrials.gov/study/NCT06686134, phase Not stated, title Comprehensive Clinical Evaluation Study of GLP-1RA, status recruiting, sponsor LI YAN, countries China, us states none listed
- nct NCT06720246, url https://clinicaltrials.gov/study/NCT06720246, phase Not stated, title Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity, status recruiting, sponsor I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio, countries Italy, us states none listed
- nct NCT07309094, url https://clinicaltrials.gov/study/NCT07309094, phase Not stated, title Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD, status recruiting, sponsor Cardenal Herrera University, countries Spain, us states none listed
- nct NCT05925959, url https://clinicaltrials.gov/study/NCT05925959, phase Not applicable, title Preoperative Weight Loss for Open Abdominal Wall Reconstruction, status recruiting, sponsor Benjamin T. Miller, countries United States, us states Illinois, Ohio
- nct NCT05681299, url https://clinicaltrials.gov/study/NCT05681299, phase Phase 4, title Effects of GH and Lirglutide on AgRP, status recruiting, sponsor Columbia University, countries United States, us states New York
- nct NCT05268237, url https://clinicaltrials.gov/study/NCT05268237, phase Phase 1/Phase 2, title Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus, status recruiting, sponsor Biolingus, countries Hong Kong, us states none listed
- nct NCT05390892, url https://clinicaltrials.gov/study/NCT05390892, phase Phase 4, title PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes, status recruiting, sponsor Brigham and Women's Hospital, countries United States, us states Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kansas, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Wisconsin
- nct NCT04575844, url https://clinicaltrials.gov/study/NCT04575844, phase Phase 4, title Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome, status recruiting, sponsor University of Virginia, countries United States, us states Virginia
- nct NCT03883412, url https://clinicaltrials.gov/study/NCT03883412, phase Phase 4, title Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007), status recruiting, sponsor University of Virginia, countries United States, us states Virginia
- nct NCT03087032, url https://clinicaltrials.gov/study/NCT03087032, phase Phase 4, title Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD), status recruiting, sponsor The First Affiliated Hospital of Xiamen University, countries China, us states none listed
- nct NCT03878706, url https://clinicaltrials.gov/study/NCT03878706, phase Not stated, title The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination, status recruiting, sponsor University of Athens, countries Greece, us states none listed

Source: https://clinicaltrials.gov/api/v2/studies?query.intr=liraglutide+OR+Victoza+OR+Saxenda&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState

## Sources

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

### 1. Drugs@FDA: Victoza injection, application 022341

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341

### 2. Drugs@FDA: Saxenda injection, application 206321

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321

### 3. DailyMed: Victoza injection prescribing information, revised October 2025

Type: label

Tier: primary

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

### 4. DailyMed: Saxenda injection prescribing information, revised June 2026

Type: label

Tier: primary

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

### 5. FDA: first generic referencing Victoza approved, 23 December 2024

Type: regulatory

Tier: primary

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes

### 6. FDA: 2025 first generic drug approvals, including liraglutide referencing Saxenda

Type: regulatory

Tier: primary

Source: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals

### 7. FDA drug shortages: liraglutide injection, currently in shortage

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c

### 8. FDA: proposal to exclude liraglutide from the 503B bulks list, 30 April 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

### 9. FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

### 10. FDA warning letter to a website offering compounded liraglutide, 20 February 2026

Type: regulatory

Tier: primary

Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026

### 11. FDA Import Alert 66-80: GLP-1 bulk drug substances, revised 9 October 2026

Type: regulatory

Tier: primary

Source: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html

### 12. Orrick: FDA moves to end large-scale compounding of GLP-1 drugs

Type: legal-analysis

Tier: legal-analysis

Source: https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs

### 13. McDermott Will & Schulte, on Mondaq: FDA takes aim at online claims for compounded GLP-1 drugs

Type: legal-analysis

Tier: legal-analysis

Source: https://www.mondaq.com/unitedstates/healthcare/1814666/fda-takes-aim-at-misleading-online-claims-for-compounded-glp-1-drugs

### 14. LEADER: liraglutide and heart outcomes in type 2 diabetes, 2016

Type: rct

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/27295427/

### 15. SCALE: liraglutide 3.0 mg for weight management, 2015

Type: rct

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/26132939/

### 16. Ellipse: liraglutide in children and teens with type 2 diabetes, 2019

Type: rct

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/31034184/

### 17. Liraglutide for teens with obesity, 2020

Type: rct

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/32233338/

### 18. Cochrane review: liraglutide for adults living with obesity, 2025

Type: systematic-review

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/41161684/

### 19. Review and meta-analysis: liraglutide for weight in children and teens, 2023

Type: systematic-review

Tier: peer-reviewed

Source: https://pubmed.ncbi.nlm.nih.gov/37672063/

### 20. BioSpace: first generic of Saxenda approved, August 2025

Type: reference

Tier: established-news

Source: https://www.biospace.com/fda/teva-brings-first-glp-1-generic-for-obesity-targets-novos-saxenda

### 21. Healio: FDA approves a generic form of liraglutide for type 2 diabetes

Type: reference

Tier: established-news

Source: https://www.healio.com/news/endocrinology/20250214/fda-approves-a-generic-form-of-liraglutide-to-treat-type-2-diabetes

Last verified: 2026-10-25.

Sources:

- https://clinicaltrials.gov/api/v2/studies?query.intr=liraglutide+OR+Victoza+OR+Saxenda&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
- https://peptideindex.ai/methodology#evidence-grade
- https://peptideindex.ai/methodology#short-answer
- https://pubmed.ncbi.nlm.nih.gov/27295427/
- https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321

[^1]: Drugs@FDA: Victoza injection, application 022341 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341
[^2]: Drugs@FDA: Saxenda injection, application 206321 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321
[^3]: DailyMed: Victoza injection prescribing information, revised October 2025 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
[^4]: DailyMed: Saxenda injection prescribing information, revised June 2026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
[^5]: FDA: first generic referencing Victoza approved, 23 December 2024 https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes
[^6]: FDA: 2025 first generic drug approvals, including liraglutide referencing Saxenda https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals
[^7]: FDA drug shortages: liraglutide injection, currently in shortage https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c
[^8]: FDA: proposal to exclude liraglutide from the 503B bulks list, 30 April 2026 https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
[^9]: FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026 https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
[^10]: FDA warning letter to a website offering compounded liraglutide, 20 February 2026 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026
[^11]: FDA Import Alert 66-80: GLP-1 bulk drug substances, revised 9 October 2026 https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html
[^12]: Orrick: FDA moves to end large-scale compounding of GLP-1 drugs https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs
[^13]: McDermott Will & Schulte, on Mondaq: FDA takes aim at online claims for compounded GLP-1 drugs https://www.mondaq.com/unitedstates/healthcare/1814666/fda-takes-aim-at-misleading-online-claims-for-compounded-glp-1-drugs
[^14]: LEADER: liraglutide and heart outcomes in type 2 diabetes, 2016 https://pubmed.ncbi.nlm.nih.gov/27295427/
[^15]: SCALE: liraglutide 3.0 mg for weight management, 2015 https://pubmed.ncbi.nlm.nih.gov/26132939/
[^16]: Ellipse: liraglutide in children and teens with type 2 diabetes, 2019 https://pubmed.ncbi.nlm.nih.gov/31034184/
[^17]: Liraglutide for teens with obesity, 2020 https://pubmed.ncbi.nlm.nih.gov/32233338/
[^18]: Cochrane review: liraglutide for adults living with obesity, 2025 https://pubmed.ncbi.nlm.nih.gov/41161684/
[^19]: Review and meta-analysis: liraglutide for weight in children and teens, 2023 https://pubmed.ncbi.nlm.nih.gov/37672063/